AcelRx Pharmaceuticals, Inc. (ACRX) |
|
0.6925 -0.027 (-3.81%)
|
03-24 11:36 |
|
Open: |
0.718 |
Pre. Close: |
0.7199 |
|
High:
|
0.718 |
Low:
|
0.67 |
|
Volume:
|
50,192 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 11:58:45 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.45 One year: 1.95 |
| Support: |
Support1: 0.56 Support2: 0.47 |
| Resistance: |
Resistance1: 1.24 Resistance2: 1.66 |
| Pivot: |
0.89  |
| Moving Average: |
MA(5): 0.68  MA(20): 1
MA(100): 1.89 MA(250): 3.6 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 18.5 %D(3): 15.8 |
| RSI: |
RSI(14): 23.2 |
| 52-week: |
High: 7.59 Low: 0.18 |
| Average Vol(K): |
3-Month: 224 (K) 10-Days: 561 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACRX ] has closed above bottom band by 29.1%. Bollinger Bands are 0.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.75 - 0.75 |
0.75 - 0.75 |
|
Low:
|
0.66 - 0.67 |
0.67 - 0.67 |
|
Close:
|
0.71 - 0.72 |
0.72 - 0.73 |
|
Company Description |
|
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California. |
Headline News |
Tue, 21 Mar 2023
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 - Yahoo Finance
Tue, 14 Mar 2023
Is AcelRx Pharmaceuticals Inc (ACRX) Stock a Smart Investment Tuesday? - InvestorsObserver
Tue, 14 Mar 2023
AcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRX - MarketWatch
Wed, 01 Mar 2023
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On ... - PR Newswire
Thu, 29 Dec 2022
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript - Yahoo Finance
Tue, 27 Dec 2022
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
-23 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
8.2e+006 (%) |
|
% Held by Institutions
|
7.35e+006 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.03e+006 |
|
EPS Est Next Qtl
|
-0.24 |
|
EPS Est This Year
|
-1.13 |
|
EPS Est Next Year
|
-0.94 |
|
Book Value (p.s.)
|
3.77 |
|
Profit Margin (%)
|
3 |
|
Operating Margin (%)
|
111.2 |
|
Return on Assets (ttm)
|
-2 |
|
Return on Equity (ttm)
|
102.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-22.5 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.91667e+006 |
|
Qtrly Earnings Growth
|
-3.021e+007 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.18 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
666620 |
|
Forward Dividend
|
534860 |
|
Dividend Yield
|
96262800% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
